Corcept Therapeutics Inc. (CORT)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Corcept Therapeutics Inc. (CORT)
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Key Insights
Critical company metrics and information
Share Price
$60.78Market Cap
$6.37 BillionTotal Outstanding Shares
104.78 Million SharesTotal Employees
352Dividend
No dividendIPO Date
April 14, 2004SIC Description
Pharmaceutical PreparationsHomepage
https://www.corcept.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $25.49 Million |
| Net Cash Flow From Operating Activities | $144.65 Million |
| Net Cash Flow From Investing Activities | $-96.15 Million |
| Net Cash Flow From Financing Activities | $-23.02 Million |
| Net Cash Flow From Operating Activities, Continuing | $144.65 Million |
| Net Cash Flow From Investing Activities, Continuing | $-96.15 Million |
| Net Cash Flow | $25.49 Million |
| Net Cash Flow From Financing Activities, Continuing | $-23.02 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Preferred Stock Dividends And Other Adjustments | $735000.00 |
| Net Income/Loss Available To Common Stockholders, Basic | $140.47 Million |
| Net Income/Loss Attributable To Parent | $141.82 Million |
| Basic Earnings Per Share | $1.36 |
| Gross Profit | $618.75 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $735000.00 |
| Diluted Earnings Per Share | $1.26 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Cost Of Revenue | $9.80 Million |
| Costs And Expenses | $485.20 Million |
| Income/Loss From Continuing Operations Before Tax | $166.34 Million |
| Income Tax Expense/Benefit, Deferred | $-40.01 Million |
| Benefits Costs and Expenses | $462.21 Million |
| Income Tax Expense/Benefit | $24.52 Million |
| Research and Development | $231.29 Million |
| Revenues | $628.55 Million |
| Selling, General, and Administrative Expenses | $244.10 Million |
| Operating Income/Loss | $143.36 Million |
| Diluted Average Shares | $334.57 Million |
| Nonoperating Income/Loss | $22.98 Million |
| Net Income/Loss | $141.82 Million |
| Income/Loss From Continuing Operations After Tax | $141.82 Million |
| Operating Expenses | $475.39 Million |
| Basic Average Shares | $308.91 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Accounts Payable | $18.58 Million |
| Inventory | $8.05 Million |
| Noncurrent Assets | $317.28 Million |
| Other Current Assets | $453.11 Million |
| Other Current Liabilities | $107.63 Million |
| Noncurrent Liabilities | $19.21 Million |
| Other Non-current Assets | $314.35 Million |
| Fixed Assets | $2.93 Million |
| Prepaid Expenses | $5.82 Million |
| Liabilities And Equity | $784.26 Million |
| Liabilities | $145.42 Million |
| Current Liabilities | $126.22 Million |
| Equity | $638.84 Million |
| Assets | $784.26 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $638.84 Million |
| Current Assets | $466.98 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.